Disease Areas
News and analysis on disease research and diagnostics.
Immatics Prices $150M Stock Offering
The firm plans to use the proceeds to advance its pipeline of T-cell receptor therapies and support their manufacturing, production, and commercialization.
AstraZeneca Advancing Plan to Launch Biomarker-Driven Drugs as Alternative to Chemo in Breast Cancer
Premium
The drugmaker wants to establish Enhertu in HER2-ultralow breast cancer and even HER2-negative tumors but remains committed to precision medicine strategies.
FDA Approves Genentech's Itovebi Combo for PIK3CA-Mutated Advanced Breast Cancer Patients
In the INAVO120 trial, Itovebi added to Pfizer's Ibrance and fulvestrant doubled progression-free survival versus Ibrance and fulvestrant alone.
In Brief This Week: ADLM, Verismo, Gemma, Denovo, Flatiron Health, Foresight, Naveris
News items for the week of Oct. 7, 2024.
The firm is gearing up for a registration-directed trial based on a positive Phase Ib readout and after discussions with US and German health authorities.
Oct 10, 2024
Gritstone Files for Chapter 11 Bankruptcy
Oct 10, 2024
Immatics to Raise $150M in Public Stock Offering
Oct 9, 2024